logo-loader
viewG Medical Innovations Holdings Ltd

Australian e-health company G Medical Innovations eyes Nasdaq listing

G Medical Innovations Holdings Ltd (ASX:GMV) CEO Yacov Geva sits down with Proactive Investors' Christine Corrado in New York to update investors on the mobile and e-health company's move to list on the Nasdaq.

Geva says the company, which specializes in software and devices that aim to reduce inefficiencies in health care delivery, will remain listed on the Australian Stock Exchange, but will begin trading on the major US exchange in early 2019.

G Medical’s key product, Prizma, is a smartphone case that transforms any smartphone into a medical monitoring device.

Quick facts: G Medical Innovations Holdings Ltd

Price: 0.045 AUD

ASX:GMV
Market: ASX
Market Cap: $19.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of G Medical Innovations Holdings Ltd named herein, including the promotion by the Company of G Medical Innovations Holdings Ltd in any Content on...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346;...

Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive...

9 minutes ago

2 min read